

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE

00 FEB 14 PM 5:43

H. D.

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Bergner - Bockorny, Inc.			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 1101 16th Street, N.W. Suite 500 City Washington State/Zip (or Country) DC 20036 USA			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name Jeffrey Bergner		Telephone 202-659-9111	5. Senate ID # 6006-164
7. Client Name <input type="checkbox"/> Self Glaxo Wellcome, Inc.		6. House ID # 31317011	

TYPE OF REPORT 8. Year 1999 Midyear (January 1-June 30) ☐ OR Year End (July 1-December 31) ☒

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ >> Termination Date _____

11. No Lobbying Activity ☐

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000 ☐

\$10,000 or more ☒ >> \$ \$80,000.00
Income (nearest \$20,000)

Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000 ☐

\$10,000 or more ☐ >> \$ _____
Expenses (nearest \$20,000)

14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.

- ☐ Method A. Reporting amounts using LDA definitions only
☐ Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
☐ Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature

Jeffrey T. Bergner

Date 2/14/00

Printed Name and Title

Jeffrey Bergner - President

Page 1 of 5

Registrant Name: Bergner - Bockorny, Inc.

Client Name: Glaxo Wellcome, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific Lobbying issues
Legislation concerning asthma.

17. House(s) of Congress and Federal agencies contacted
House of Representatives
Senate

☐ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Bergner, Jeffrey</u>		<u>No</u>
<u>Bockorny, David</u>		<u>No</u>
<u>Castagnetti, David</u>	<u>Chief of Staff, U.S. Senate</u>	<u>No</u>
<u>Hawkins, James</u>	<u>Health Policy Advisor</u>	<u>No</u>
<u>Reese, Brenda</u>	<u>Legislative Coordinator - House Rep. Conference</u>	<u>No</u>
<u>Schulman, Melissa</u>	<u>Policy Director, U.S. House of Reps.</u>	<u>No</u>
<u>Smith, Margaret</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature Jeffrey T. Bergner Date 2/14/00
Printed Name and Title Jeffrey Bergner - President Page 2 of 5

Registrant Name: Bergner - Bockorny, Inc.

Client Name: Glaxo Wellcome, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues
**H.R.664, Prescription Drug Fairness for Seniors Act of 1999,
Medicaid and Medicare reform.**

17. House(s) of Congress and Federal agencies contacted
**House of Representatives
Senate**

☐ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Bergner, Jeffrey		No
Bockorny, David		No
Castagnetti, David	Chief of Staff, U.S. Senate	No
Hawkins, James	Health Policy Advisor	No
Reese, Brenda	Legislative Coordinator - House Rep. Conference	No
Schulman, Melissa	Policy Director, U.S. House of Reps.	No
Smith, Margaret		No

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature

Jeffrey T. Bergner

Date 2/14/00

Printed Name and Title

Jeffrey Bergner - President

Page **3** of **5**

Registrant Name: Bergner - Bockorny, Inc.

Client Name: Glaxo Wellcome, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific Lobbying issues
Patent reform legislation.

17. House(s) of Congress and Federal agencies contacted
House of Representatives
Senate

☐ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Bergner, Jeffrey</u>		<u>No</u>
<u>Bockorny, David</u>		<u>No</u>
<u>Castagnetti, David</u>	<u>Chief of Staff, U.S. Senate</u>	<u>No</u>
<u>Hawkins, James</u>	<u>Health Policy Advisor</u>	<u>No</u>
<u>Reese, Brenda</u>	<u>Legislative Coordinator - House Rep. Conference</u>	<u>No</u>
<u>Schulman, Melissa</u>	<u>Policy Director, U.S. House of Reps.</u>	<u>No</u>
<u>Smith, Margaret</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature: Jeffrey T. Bergner Date: 2/14/00
Printed Name and Title: Jeffrey Bergner - President Page 4 of 5

Registrant Name: Bergner - Bockorny, Inc.

Client Name: Glaxo Wellcome, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific Lobbying issues
Africa Trade Bill. International agreements concerning CFC's.

17. House(s) of Congress and Federal agencies contacted
House of Representatives
Senate

☐ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Bergner, Jeffrey</u>		<u>No</u>
<u>Bockorny, David</u>		<u>No</u>
<u>Castagnetti, David</u>	<u>Chief of Staff, U.S. Senate</u>	<u>No</u>
<u>Hawkins, James</u>	<u>Health Policy Advisor</u>	<u>No</u>
<u>Rcese, Brenda</u>	<u>Legislative Coordinator - House Rep. Conference</u>	<u>No</u>
<u>Schulman, Melissa</u>	<u>Policy Director, U.S. House of Reps.</u>	<u>No</u>
<u>Smith, Margaret</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature

Jeffrey T. Bergner

Date 2/14/00

Printed Name and Title

Jeffrey Bergner - President

Page 5 of 5